3 Undervalued Pharmaceuticals Stocks for Tuesday, September 15
Discover the top 3 undervalued Pharmaceuticals stocks for Tuesday, September 15 based on AAII’s Stock Grades.Michael Rose
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Perrigo Company plc provides over-the-counter health and wellness solutions in the United States, Europe, and internationally. The company operates through Consumer Self-Care Americas and Consumer Self-Care International segments. It offers upper respiratory products, including cough suppressants, expectorants, and sinus and allergy relief; nutrition products consisting of infant formulas and oral electrolyte beverages; digestive health products, including antacids, anti-diarrheal, and anti-heartburn; pain and sleep-aids products comprising pain relievers and fever reducers; and oral care products, which include toothbrushes, toothbrush replacement heads, floss, flossers, whitening products, and toothbrush covers. The company also offers healthy lifestyle products, such as smoking cessation and well-being products; skin care products consisting of dermatological care, scar management, lice treatment, and other products for various skin conditions; women’s health products comprising feminine hygiene and contraceptives; vitamins, minerals, and supplements; and other miscellaneous self-care products. It sells its products under the Compeed, Dr. Fresh, Firefly, Good Sense, Good Start, Mederma, Nasonex, Plackers, Prevacid24HR, REACH, Rembrandt, Steripod, Opill, Solpadeine, Coldrex, Physiomer, NiQuitin, ACO, ellaOne, and Compeed brands. The company also offers contract manufacturing services. It sells its products through retail drug, supermarket, and mass merchandise chains; e-commerce stores; wholesalers; pharmacies; drug and grocery retailers; and para-pharmacies. The company was formerly known as Perrigo Company and changed its name to Perrigo Company plc in December 2013. Perrigo Company plc was founded in 1887 and is headquartered in Dublin, Ireland.
Commentary & Analysis
Which Is a Better Investment, Crinetics Pharmaceuticals, Inc. or Perrigo Company plc Stock?
Learn more about whether Crinetics Pharmaceuticals, Inc. or Perrigo Company plc is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.Michael Rose
Which Is a Better Investment, Nektar Therapeutics or Perrigo Company plc Stock?
Learn more about whether Nektar Therapeutics or Perrigo Company plc is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.Tudor Pop
Is Perrigo Company plc (PRGO) Overvalued?
We dive into why Perrigo Company plc (PRGO) could be considered overvalued on 2026-08-06, based on AAII’s Value Score and Grade.Michael Rose
Why Perrigo Company plc’s (PRGO) Stock Is Up 21.97%
As of Wednesday, August 05, Perrigo Company plc’s PRGO share price has surged by 21.97%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
Financial Summary
| Share Statistics | PRGO | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $1,894.2 | $608.6 | 53% |
|
| Shares Out (Mil) | 139.6 | 43.1 | 69% |
|
| Institutional Ownership | 99.6% | 83.7% | 91% |
|
| Float (Mil) | 138.1 | 45.1 | 67% |
|
| Beta | 0.54 | 0.73 | 31% |
|
| Avg Daily Volume (000s) | 2,442 | 309 | 86% |
|
| Price Change (52-week) |
(39.5%) | 65.2% | 21% |
|
| Growth | PRGO | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 0.8% | 6.7% | 19% |
|
| Net Income (5yr) | (54.4%) | (1.5%) | 6% |
|
| EPS (5yr) | (54.0%) | 15.1% | 3 |
|
| Dividends (5yr) | 5.2% | 0.0% | 81% |
|
| Cash Flow (5yr) | (15.8%) | (15.0%) | 46% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 4 | 5 | 5 | |
| Current EPS | $0.532 | $2.188 | $2.398 | |
| Month Ago EPS | $0.532 | $2.188 | $2.398 | |
| # Rev Up | 0 | 0 | 0 | |
| # Rev Down | 1 | 1 | 1 | |
| Three Months Ago EPS | $0.568 | $2.108 | $2.362 | |
| Year/Year Chg | (15.6%) | (121.6%) | (126.6%) | |
| Financials | PRGO | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $4,145 | $317 | 72% |
|
| Net Income (TTM) (Mil) | ($1,735) | ($11) | 1% |
|
| EPS (TTM) | ($12.484) | ($0.700) | 4% |
|
| Operating Cash Flow (TTM) (Mil) | $196 | ($6) | 59% |
|
| Net Cash Flow (TTM) (Mil) | ($55) | $5 | 19% |
|
| Long-Term Debt (Q1) (Mil) | $3,440 | $6 | 81% |
|
| Enterprise Value (Q1) (Mil) | $5,079 | $524 | 63% |
|
| Valuation | PRGO | Industry Median |
Percentile (All Stocks) |
|
| P/B | 0.75 | 2.60 | 14% |
|
| P/E | na | 17.0 | na |
|
| Dividend Yield | 8.5% | 0.0% | 98% |
|
| PEG (5yr hist) | na | 1.1 | na |
|
| Ratios | PRGO | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 33.3% | 68.8% | 40% |
|
| Net Margin | (41.9%) | 0.8% | 13% |
|
| ROA | (19.6%) | (22.5%) | 20% |
|
| ROE | (49.6%) | (21.8%) | 15% |
|
| Liabilities to Assets | 66.9% | 32.8% | 62% |
|
| F-Score | 4 | 3 | na |
|
Passing Stock Screens
As of 9/14/2026, from a list of 60 stock screening strategies,
GURU STRATEGY
Kirkpatrick Bargain Screen
Factors: Value, Momentum
Investing model outlined in Charles Kirkpatrick's book, Beat the Market: Invest by Knowing What Stocks to Buy and What Stocks to Sell.
| Performance Since Inception: | 6.9% |
| +/- S&P 500: | -0.6 |
